Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received for publication May 4, 2019
- Accepted for publication July 6, 2019
- Published online September 3, 2019.
Copyright & Usage
© 2019 by the Society of Nuclear Medicine and Molecular Imaging.
Author Information
- Johannes Czernin,
- Ida Sonni,
- Aria Razmaria and
- Jeremie Calais
- Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California
- For correspondence or reprints contact: Johannes Czernin, Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, 10833 Le Conte Ave., Los Angeles CA 90095-7370. E-mail: jczernin{at}mednet.ucla.edu
Statistics from Altmetric.com
Cited By...
Article usage
Jump to section
Related Articles
Cited By...
- The Future of Nuclear Medicine in the United States
- Redesigned Curricula, Stringent Licensing Criteria, and Integrated Independence Are Conditions for a Bright Future for Nuclear Medicine in the United States
- How Many Theranostics Centers Will We Need in the United States?
- PSMA Expression Assessed by PET Imaging Is a Required Biomarker for Selecting Patients for Any PSMA-Targeted Therapy
- Diversity, Equity, and Inclusion in Academic Nuclear Medicine: National Survey of Nuclear Medicine Residency Program Directors
- The Disappearing Act of Nuclear Medicine in The Netherlands: Just a New Trick by the Great Harry Houdini?
- The New Integrated Nuclear Medicine and Radiology Residency Program in The Netherlands: Why Do Residents Choose to Subspecialize in Nuclear Medicine and Why Not?
- Diversity, Not Divisiveness, Is the Future of Nuclear Medicine
- Reply: Diversity, Not Divisiveness, Is the Future of Nuclear Medicine
- Nuclear Medicine, Molecular Imaging, and Theranostics: The Future Is Bright
- The Standard of Care: From Nuclear Radiology to Nuclear Medicine
- Of Sheep and Wolves: Curtailing Coverage for Essential Imaging Tests Based on Flawed Use and Cost Arguments
- Driving the Future of Nuclear Medicine
- Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine